

European stakeholder learnings regarding biosimilars: Part I – improving biosimilar understanding and adoption

BioDrugs

Liese Barbier^{1*}, Steven Simoens¹, Arnold G. Vulto^{1,2+*}, Isabelle Huys¹⁺

¹KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium

²Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands

+ Joint last author: these authors contributed equally to this work

* Corresponding author:

Arnold G. Vulto Contact: a.vulto@gmail.com

Liese Barbier Contact: liese.barbier@kuleuven.be

Online Resource 2. Inclusion and exclusion criteria applied in selection of identified articles

Inclusion and exclusion criteria applied in selection of identified articles	
Inclusion criteria	Exclusion criteria
<ul style="list-style-type: none">- Reported perspectives of at least one HCP (physician, pharmacist, nurse) or patient stakeholder group- Stakeholder perspective reporting based on original research (e.g. via surveys, interviews, focus group discussions)	<ul style="list-style-type: none">- Paper reporting about the perspective solely of non-HCP or patient stakeholder group (e.g. papers with a sole focus on the payer perspective)- Non original research oriented papers, illustrating a stakeholder perspective such as literature reviews, expert opinion papers, stakeholder opinion papers or position statements

HCP: healthcare professional